Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Cases Secondary to Topical Medications
- 6 March 2026
- journal article
- review article
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (3)
Abstract
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are typically triggered by systemic medications but can also result from topical agents. In this systematic review of SJS/TEN cases caused by topical agents, the drug culprits, disease characteristics, and outcomes were comparable to systemic cases. Our findings highlight that topical formulations, though generally considered safer, can induce SJS and TEN, underscoring the need for clinician awareness, early recognition and accurate reporting.Keywords
This publication has 9 references indexed in Scilit:
- Updates in the pathogenesis of SJS/TENAllergology International, 2025
- Stevens-Johnson Syndrome Secondary to Topical OfloxacinAmerican Journal of Case Reports, 2023
- Asian Race and Primary Open-Angle Glaucoma: Where Do We Stand?Journal of Clinical Medicine, 2022
- Methodological quality and synthesis of case series and case reportsBMJ Evidence-Based Medicine, 2018
- A rare case of topical methazolamide ophthalmic solution causing death due to toxic epidermal necrolysisClinical and Experimental Dermatology, 2018
- Can gender difference in prescription drug use be explained by gender-related morbidity?: a study on a Swedish population during 2006BMC Public Health, 2014
- Toxic Epidermal Necrolysis in a Patient with HLA-B*5901 Haplotype Caused by Topical and Oral Carbonic Anhydrase InhibitorsAnnals of Dermatology, 2014
- Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-StudyJournal of Investigative Dermatology, 2008
- Toxic Epidermal Necrolysis Induced by the Topical Carbonic Anhydrase Inhibitors Brinzolamide and DorzolamideAnnals of Dermatology, 2008